Operating
Stemcentrx Impairment Charge
Amgen Stemcentrx Impairment Charge decreased by 100.0% to $0.00 in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 100.0%, from $800.00M to $0.00. This is a positive signal — lower values indicate better performance for this metric.
Analysis
StatementCash Flow Statement
SectionOperating
CategoryCapital Allocation
SignalLower is better
VolatilityVolatile
First reportedQ1 2023
Last reportedQ1 2026Apr 30, 2026
How to read this metric
An impairment charge signals that previous investments or acquisitions are underperforming expectations.
Detailed definition
This represents a non-cash impairment charge taken against the carrying value of specific acquired assets or goodwill wh...
Peer comparison
Company-specific; peers in M&A-heavy sectors may report similar charges following unsuccessful acquisitions.
Metric ID:
abbv_stemcentrx_impairmentHistorical Data
11 periods
| Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $212.75M | $212.75M | $212.75M | $212.75M | $68.00M | $0.00 | $61.00M | $30.00M | $800.00M | $400.00M | $0.00 |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | -68.0% | -100.0% | — | -50.8% | >999% | -50.0% | -100.0% |
| YoY Change | — | — | — | — | -68.0% | -100.0% | -71.3% | -85.9% | >999% | +555.7% | -100.0% |
Range$0.00 – $800.00M
CAGR-100.0%
Avg YoY Growth+172.4%
Median YoY Growth-71.3%
Current Streak2 quarters decline
Stemcentrx Impairment Charge at Other Companies
Frequently Asked Questions
- What is Amgen's stemcentrx impairment charge?
- Amgen (AMGN) reported stemcentrx impairment charge of $0.00 in Q1 2026.
- How has Amgen's stemcentrx impairment charge changed year-over-year?
- Amgen's stemcentrx impairment charge decreased by 100.0% year-over-year, from $800.00M to $0.00.
- What does stemcentrx impairment charge mean?
- Non-cash write-down of the value of acquired assets.